Cigna Incentive Program Offers $500 to Switch from Biologics to Biosimilars, Drug Savings Could Reach $375 Billion
In an effort to promote biosimilars, Cigna is offering $500 if customers switch to a lower-cost offering. Experts project that [...]
JAMA Article Finds Medicare Overspent on Generics by $2.6 Billion, Costco Delivered Better Value
A recent article published in JAMA Internal Medicine compares Medicare drug spending on generics to Costco. The researchers found that [...]
With sweeping executive order, Biden puts drug pricing, anti-competitive strategies in the crosshairs
With sweeping executive order, Biden puts drug pricing, anti-competitive strategies in the crosshairs fkansteiner Mon, 07/12/2021 - 09:51 Read the [...]
2021 Managed Healthcare Executive Pharmacy Survey Respondents Consider Impact of Federal Legislation on Drug Prices
The final portion of Managed Healthcare Executive’s 2021 Pharmacy Survey focused on federal legislation as a mechanism to reduce prescription [...]
Which Factors Drive Specialty Drug Expenditures?
The Managed Healthcare Executive Pharmacy Survey asked respondents questions related to specialty drug expenditures in 2021. Most of the 225 [...]
CEVR Researcher and Author Dan Ollendorf Discusses QALYs, Reducing Prescription Drug Prices Using Value, and HTAs
Dr. Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts University Medical [...]
Will Senate Finance Committee Chair Use Domestic Reference Pricing in Prescription Drug Negotiation Plan?
Allowing Medicare to negotiate prescription drug costs is one method of reducing healthcare costs. Now, Senate Finance Committee Chair Ron [...]
Prescription Drug Prices Increased 3.1% in July 2020 According to GoodRx
GoodRx found that 52 drugs rose in price by 3.1% in July 2020, while no generics upped their prices. Zogenix’s [...]
Vanderbilt and Stanford Professors Discuss 2021 Drug Pricing Reform in JAMA Article, Note Power of Value Assessments and Medicare Negotiation During COVID-19 Pandemic
Dr. Stacie Dusetzina of Vanderbilt University School of Medicine and Dr. Michelle Mello of Stanford Law School and Stanford School [...]
ICER Considers Fair Access Principles as Aduhelm Price Continues to Incense Critics
The Institute for Clinical and Economic Review (ICER) recently published its protocol detailing how it will gauge access to prescription [...]
Despite WHO Recommendation, COVID-19 Drug Too Costly and Inaccessible; Will Roche Give Up Monopoly?
The World Health Organization (WHO) has recommended the use of monoclonal antibody tocilizumab in cases of severe COVID-19 illness. However, [...]
2021 Managed Healthcare Executive Pharmacy Survey Results Include Increased Focus on Price Transparency to Reduce Prescription Drug Costs
Managed Healthcare Executive is publishing the results from its recent survey. According to the more than 225 respondents, reducing drug [...]
Acting FDA Commissioner Janet Woodcock Pushes HHS Inspector General to Open Biogen Investigation
Aduhelm's surprising drug approval continues to make waves throughout the country. In addition to commanding a steep price, a newly [...]
The FDA Unhappy With Biogen’s 9-Year Postmarket Timeline, Asks For Prompt Aduhelm Data
The Food and Drug Administration (FDA)’s approval of Biogen’s Aduhelm is facing widespread criticism, especially after an undisclosed pre-approval meeting [...]
Interview with University of Washington Professor and Dean Sheds Light on Reimbursing Novel Cell and Gene Therapies
The Evidence Base interviewed the University of Washington’s Sean Sullivan on the intricacies of reimbursement for novel therapies. Although these [...]
Recent Publication Considers Outcome-Based Approaches for Rare Disease Therapies
A recent article published in PharmacoEconomics considers outcomes-based approaches that may be used when considering the approval of rare disease [...]
ISMPP Hosts July Webinar on the Value of its CMPP Credential for Medical Publication Professionals
The International Society for Medical Publication Professionals (ISMPP) will hold a webinar on July 21st at 11:00 AM EDT on [...]
The Evidence Base Discusses RWE and HTA Spring Trends
Sreeram Ramagopalan of The Evidence Base discusses real world evidence (RWE) and health technology association (HTA) trends for April and [...]
Upcoming Asia Pacific ISMPP Webinar on Challenges in Publishing RWE Studies and Solutions
The International Society for Medical Publication Professionals (ISMPP) will host a webinar at 9:00 PM EDT on July 14th / [...]
ISPOR Value in Health Article Discusses Generating Cost-Effectiveness Analyses Using US Healthcare Data Based on Age and Disease
ISPOR’s Value in Health has published an article cataloguing healthcare costs and noting that cost-effectiveness analyses may allow for future [...]
Walmart Enters Insulin Industry Amid Criticism
Walmart has announced that it will sell a cheaper version of insulin. Although this move is projected to pass substantial [...]
Upcoming IQVIA Webinar on Optimizing Your Organization’s Approach to RWE
IQVIA will hold a one-hour webinar at 2:00 PM ET on July 22nd on real world evidence (RWE). The webinar [...]
Register Today for ISPOR Webinar on NICE’s Strategic Approach to RWE and Novel Therapy Approval
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s next installment of its Signal series will take place July 15th [...]
Supreme Court to Hear Hospital Drug Pricing Case in Medicare Test
The Supreme Court will hear a case on Medicare drug price determination. This is one of many tests of healthcare [...]
Former HHS Secretary Calls for Investigation into FDA’s Aduhelm Approval
Former Secretary of Health and Human Services (HHS) Donna Shalala has called for an investigation into the widely criticized Aduhelm [...]